# Truqap (capivasertib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/capivasertib

> The FDA approved Truqap (capivasertib), sponsored by ASTRAZENECA PLC (AZN), on November 16, 2023 for to treat breast cancer that meets certain disease criteria.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Truqap (capivasertib) FDA approved?

Yes. The FDA approved Truqap (capivasertib), sponsored by ASTRAZENECA PLC (AZN), on November 16, 2023 for to treat breast cancer that meets certain disease criteria. FDA novel drug approvals: "Truqap | capivasertib | 11/16/2023 | To treat breast cancer that meets certain disease criteriaDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/capivasertib)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/capivasertib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Truqap (capivasertib) |
| Codes | AZD5363 |
| Sponsor | ASTRAZENECA PLC (AZN) https://sec-api.dev/companies/azn/catalysts |
| Indications | To treat breast cancer that meets certain disease criteria, [Breast Cancer](https://sec-api.dev/indications/breast-cancer), [Locally Advanced (Inoperable) or Metastatic Breast Cancer](https://sec-api.dev/indications/locally-advanced-inoperable-or-metastatic-breast-cancer), [Prostate Cancer](https://sec-api.dev/indications/prostate-cancer), [Triple Negative Breast Neoplasms](https://sec-api.dev/indications/triple-negative-breast-neoplasms) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### November 16, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat breast cancer that meets certain disease criteria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Truqap | capivasertib | 11/16/2023 | To treat breast cancer that meets certain disease criteriaDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA218197 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20231116, review_priority PRIORITY; sponsor_name ASTRAZENECA; product TRUQAP (CAPIVASERTIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218197%22

### March 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Prostate Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05348577 (Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-04 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05348577

### March 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Triple Negative Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03997123 (Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-16 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT03997123

### April 30, 2026: FDA advisory committee meeting

- Status: completed, positive. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "On the afternoon of April 30, 2026, the Committee will discuss supplemental new drug application (sNDA) 218197/S-004, for Truqap (capivasertib) tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) is in combination with abiraterone for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) that is PTEN-deficient as detected by an FDA-approved test." https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-30-2026-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04302026
- Federal Register meeting notice: "On the afternoon of April 30, 2026, the Committee will discuss supplemental new drug application (sNDA) 218197/S-004, for Truqap (capivasertib) tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) is in combination with abiraterone for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) that is PTEN-deficient as detected by an FDA-approved test." https://www.federalregister.gov/documents/2026/03/09/2026-04497/oncologic-drugs-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request-for
- FDA advisory committee calendar: "VOTE: Based on the CAPItello-281 results, does the benefit of adding capivasertib to abiraterone and prednisone outweigh the risk for the proposed indication? Vote Result: Yes: 7 No: 1 Abstain: 1" https://www.fda.gov/media/192813/download

### June 12, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218197 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority STANDARD; sponsor_name ASTRAZENECA; product TRUQAP (CAPIVASERTIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218197%22

### September 16, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218197 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260916, review_priority STANDARD; sponsor_name ASTRAZENECA; product TRUQAP (CAPIVASERTIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218197%22

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06635447 (Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06635447

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06635447 (Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06635447

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Locally Advanced (Inoperable) or Metastatic Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04862663 (Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT04862663

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Locally Advanced (Inoperable) or Metastatic Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04862663 (Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT04862663

## Same indication

- [AAA817](https://sec-api.dev/pdufa/aaa817) (NVS)
- [Piqray (alpelisib)](https://sec-api.dev/pdufa/alpelisib) (NVS)
- [Arm a: gedatolisib + palbociclib + fulvestrant](https://sec-api.dev/pdufa/arm-a-gedatolisib-palbociclib-fulvestrant) (CELC)
- [Dato-dxd](https://sec-api.dev/pdufa/dato-dxd) (AZN)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [Revtorpyk (gedatolisib)](https://sec-api.dev/pdufa/gedatolisib) (CELC)
- [Ifinatamab deruxtecan](https://sec-api.dev/pdufa/ifinatamab-deruxtecan) (MRK)
- [Palazestrant](https://sec-api.dev/pdufa/palazestrant) (OLMA)
- [IBRANCE® (palbociclib)](https://sec-api.dev/pdufa/palbociclib) (PFE)
- [Pcs6422 and capecitabine](https://sec-api.dev/pdufa/pcs6422-and-capecitabine) (PCSA)
- [PF-07220060](https://sec-api.dev/pdufa/pf-07220060) (PFE)
- [PF-07248144](https://sec-api.dev/pdufa/pf-07248144) (PFE)
- [Sv-br-1-gm](https://sec-api.dev/pdufa/sv-br-1-gm) (BCTX)
- [Talazoparib plus enzalutamide](https://sec-api.dev/pdufa/talazoparib-plus-enzalutamide) (PFE)

Calendar months: [March 2026](https://sec-api.dev/fda-calendar/2026-03), [October 2026](https://sec-api.dev/fda-calendar/2026-10), [November 2027](https://sec-api.dev/fda-calendar/2027-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/capivasertib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Truqap (capivasertib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/capivasertib

```bibtex
@misc{secapidev_pdufa_capivasertib_20261116,
  title        = {Truqap (capivasertib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/capivasertib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_capivasertib_20261116","title":"Truqap (capivasertib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/capivasertib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
